Cullen Buchanan1, Manreet Kanwar2, John R Cockcroft3, Barry McDonnell3, Eric J Stöhr3,4, William K Cornwell5. 1. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 2. Cardiovascular Institute at Allegheny Health Network, Pittsburgh, PA, USA. 3. School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, CF5 2YB, UK. 4. Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York City, NY, USA. 5. Department of Medicine-Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Abstract
NEW FINDINGS: LVAD patients are predisposed to hypertension which may increase the risk of stroke. Hypertension may result from markedly elevated levels of sympathetic nerve activity, which occurs through a baroreceptor-mediated pathway in response to chronic exposure to a non-physiologic (and reduced) pulse. Cerebral autoregulatory processes appear to be preserved in the absence of a physiologic pulse. Nevertheless, the rate of ischemic/embolic and hemorrhagic stroke is unacceptably high and is a major cause of morbidity and mortality in these patients. Despite normalization of a resting cardiac output, LVAD patients suffer from persistent, severe reductions in functional capacity. ABSTRACT: Current generation left ventricular assist devices (LVADs) have led to significant improvements in survival compared to medical therapy alone, when used for management of patients with advanced heart failure. However, there are a number of side-effects associated with LVAD use, including hypertension, gastrointestinal bleeding, stroke, as well as persistent and severe limitations in functional capacity despite normalization of a resting cardiac output. These issues are, in large part, related to chronic exposure to a non-physiologic pulse, which contributes to a hyperadrenergic environment characterized by markedly elevated levels of sympathetic nerve activity through a baroreceptor-mediated pathway. In addition, these machines are unable to participate in, or contribute to, normal cardiovascular/autonomic reflexes that attempt to modulate flow through the body. Efforts to advance device technology and develop biologically sensitive devices may resolve these issues, and lead to further improvements in quality-of-life, functional capacity, and ultimately, survival, for the patients they support.
NEW FINDINGS:LVADpatients are predisposed to hypertension which may increase the risk of stroke. Hypertension may result from markedly elevated levels of sympathetic nerve activity, which occurs through a baroreceptor-mediated pathway in response to chronic exposure to a non-physiologic (and reduced) pulse. Cerebral autoregulatory processes appear to be preserved in the absence of a physiologic pulse. Nevertheless, the rate of ischemic/embolic and hemorrhagic stroke is unacceptably high and is a major cause of morbidity and mortality in these patients. Despite normalization of a resting cardiac output, LVADpatients suffer from persistent, severe reductions in functional capacity. ABSTRACT: Current generation left ventricular assist devices (LVADs) have led to significant improvements in survival compared to medical therapy alone, when used for management of patients with advanced heart failure. However, there are a number of side-effects associated with LVAD use, including hypertension, gastrointestinal bleeding, stroke, as well as persistent and severe limitations in functional capacity despite normalization of a resting cardiac output. These issues are, in large part, related to chronic exposure to a non-physiologic pulse, which contributes to a hyperadrenergic environment characterized by markedly elevated levels of sympathetic nerve activity through a baroreceptor-mediated pathway. In addition, these machines are unable to participate in, or contribute to, normal cardiovascular/autonomic reflexes that attempt to modulate flow through the body. Efforts to advance device technology and develop biologically sensitive devices may resolve these issues, and lead to further improvements in quality-of-life, functional capacity, and ultimately, survival, for the patients they support.
Authors: Antonio C P Barretto; Amilton C Santos; Robinson Munhoz; Maria U P B Rondon; Fábio G Franco; Ivani C Trombetta; Fabiana Roveda; Luciana N J de Matos; Ana M W Braga; Holly R Middlekauff; Carlos E Negrão Journal: Int J Cardiol Date: 2008-06-26 Impact factor: 4.164
Authors: William K Cornwell; Takashi Tarumi; Abigail Stickford; Justin Lawley; Monique Roberts; Rosemary Parker; Catherine Fitzsimmons; Julius Kibe; Colby Ayers; David Markham; Mark H Drazner; Qi Fu; Benjamin D Levine Journal: Circulation Date: 2015-10-28 Impact factor: 29.690
Authors: Jerry D Estep; Randall C Starling; Douglas A Horstmanshof; Carmelo A Milano; Craig H Selzman; Keyur B Shah; Matthias Loebe; Nader Moazami; James W Long; Josef Stehlik; Vigneshwar Kasirajan; Donald C Haas; John B O'Connell; Andrew J Boyle; David J Farrar; Joseph G Rogers Journal: J Am Coll Cardiol Date: 2015-10-20 Impact factor: 24.094
Authors: J N Cohn; T B Levine; M T Olivari; V Garberg; D Lura; G S Francis; A B Simon; T Rector Journal: N Engl J Med Date: 1984-09-27 Impact factor: 91.245
Authors: William K Cornwell; Takashi Tarumi; Vincent L Aengevaeren; Colby Ayers; Punag Divanji; Qi Fu; Dean Palmer; Mark H Drazner; Dan M Meyer; Brian T Bethea; Jeffrey L Hastings; Naoki Fujimoto; Shigeki Shibata; Rong Zhang; David W Markham; Benjamin D Levine Journal: J Heart Lung Transplant Date: 2014-08-28 Impact factor: 10.247
Authors: Janice Huang; Barry J McDonnell; Justin S Lawley; Jessica Byrd; Eric J Stöhr; William K Cornwell Journal: Exerc Sport Sci Rev Date: 2022-10-01 Impact factor: 6.642
Authors: Christine Sailer; Hannah Edelmann; Cullen Buchanan; Pedro Giro; Matthew Babcock; Christine Swanson; Melanie Spotts; Margaret Schulte; Ashley Pratt-Cordova; Greg Coe; Mark Beindorff; Robert L Page; Amrut V Ambardekar; Jay D Pal; Wendy Kohrt; Eugene Wolfel; Justin S Lawley; Takashi Tarumi; William K Cornwell Journal: Circ Heart Fail Date: 2021-01-19 Impact factor: 8.790